from patients with non-PH IPF in a cohort study (8).This may be a result of the absence of severe PH in these patients, or because of differences in the mechanisms driving PH in IPF versus PAH.We conclude that nintedanib shows disadvantageous effects in PAH, and future investigations are needed to reveal the precise underlying mechanisms.Moreover, the effect of this agent on pulmonary hemodynamics in patients with IPF and severe accompanying PH should be investigated in future studies.
No takes yet. Share an insight, caveat, or question.
McKown et al. (2018) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: